LETTER TO THE EDITOR
Brain-derived neurotrophic factor as a potential biomarker for sarcopenia and frailty in hemodialysis patients
First published: 22 July 2021
No abstract is available for this article.
References
- 1Xu R, Miao L, Yang C, Zhu B. Brain-derived neurotrophic factor: an available biomarker to predict and diagnose sarcopenia in hemodialysis patients? Geriatr Gerontol Int 2021; 21: 542–543.
- 2Miyazaki S, Iino N, Koda R, Narita I, Kaneko Y. Brain-derived neurotrophic factor is associated with sarcopenia and frailty in Japanese hemodialysis patients. Geriatr Gerontol Int 2021; 21: 27–33.
- 3Watanabe H, Enoki Y, Maruyama T. Sarcopenia in chronic kidney disease: factors, mechanisms, and therapeutic interventions. Biol Pharm Bull 2019; 42: 1437–1445.
- 4Lin YT, Wu PH, Liang SS et al. Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis. Sci Rep 2019; 9: 20388.
- 5Zhu B, Jin LN, Shen JQ et al. Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: a prospective single-center cohort study. Sci Rep 2018; 8: 12250.
